Controversies surrounding iron chelation therapy for MDS

Area of Science:

• Hematology
• Oncology
• Transfusion Medicine

Background:

• Myelodysplastic syndromes (MDS) often lead to anemia requiring red blood cell transfusions.
• Transfusion-dependent anemia in MDS patients poses a risk of iron overload (IOL).
• IOL is a known complication in other transfusion-dependent anemias like beta-thalassemia major, impacting organ function and survival.

Purpose of the Study:

• To review the impact of IOL in MDS and stem cell transplantation (SCT).
• To discuss potential mechanisms of iron toxicity, including oxidative stress.
• To evaluate the effects of iron reduction strategies on organ function and survival in MDS.

Main Methods:

• Review of existing non-randomized studies and emerging data on IOL in MDS.
• Analysis of data concerning the impact of IOL on survival and organ function.
• Examination of the role of iron chelation therapy in managing IOL.

Main Results:

• Non-randomized studies suggest IOL adversely affects survival in lower-risk MDS.
• Emerging data indicate IOL may negatively impact outcomes in higher-risk MDS and SCT.
• Iron reduction may improve organ function and survival, but definitive trial data are pending.

Conclusions:

• IOL is a significant concern in MDS, potentially affecting patient outcomes.
• Iron chelation therapy, while beneficial in other conditions, requires careful risk-benefit assessment in MDS due to cost and toxicity.
• Further clinical trials are needed to confirm the benefits of iron reduction in MDS and SCT.